by In2Pharma | Jun 21, 2022 | News
The Netherlands On March 30, 2022, the Dutch Health Authorities (MEB) updated the local policy regarding aRMM which is applicable for new and updated materials. No changes are required for aRMM that are already approved by MEB nor for ongoing procedures. The most...
by In2Pharma | Jun 22, 2021 | News
The Netherlands The Medicines Evaluation Board (MEB) has amended its policy regarding the national implementation of ‘additional Risk Minimization Measures’ (aRMM) (MEB 45). This is still a draft version. The main changes are: 1. Clarification of the...
by In2Pharma | Jun 11, 2021 | News
The Netherlands The Medicines Evaluation Board (MEB) has amended its policy regarding the labeling of medicines for humans (MEB 6). The MEB recognizes the value that pictograms on the packaging can have to clarify the information. Pictograms on the packaging of...
by In2Pharma | Jul 7, 2020 | News
The Netherlands On the basis of scientific conditions, the Medicines Evaluation Board (MEB) will draw up a list of medicines for which switching is undesirable. It will do this in the interests of patient safety. Medicines with the same active ingredient, dosage and...
by In2Pharma | Jun 11, 2020 | News
The Netherlands The Medicines Evaluation Board (MEB) recently revised 2 policy documents relating to the requirements for product information: “labelling of pharmaceutical products” and “Nomenclature of pharmaceutical products”. The revision only applies to medicinal...
